Xbrane: We Are Not Convinced On European IQVIA Ranibizumab Data
Positive Cash Flow Ambition Pushed Back Amid Challenges, Continued Development Costs
Swedish biosimilars player Xbrane spoke candidly about its recent launch of the company’s first product, the Stada-partnered Ximluci biosimilar to Lucentis in Europe, as it updated on the company’s ongoing hunt for a new US commercialization partner.
